Exercise-Induced Protein CLCF1 Supports Muscle and Bone Health in Aging

New research uncovers the role of the protein CLCF1, produced during exercise, in improving muscle and bone health in aging, paving the way for targeted therapies against age-related musculoskeletal decline.
Recent research has identified a vital protein called CLCF1 (cardiotrophin-like cytokine factor 1) that is produced during physical activity and plays a critical role in maintaining muscle and bone strength, especially in older adults. The study, published in Nature Communications and led by Dr. Yong Ryoul Yang from KRIBB and Professor Nak-Sung Kim from Chonnam National University, uncovered how this protein mediates exercise benefits at the molecular level.
The research team found that blood levels of CLCF1 increase significantly in younger individuals after a single exercise session, whereas older adults only show an increase after prolonged, regular exercise over 12 weeks. These findings suggest that the production of CLCF1 diminishes with age, contributing to the reduced effectiveness of exercise in combating muscle and bone decline in elderly populations.
Experimental studies on aged mice demonstrated that administering CLCF1 improved muscle strength and increased bone density. Conversely, blocking CLCF1's activity rendered exercise less effective, highlighting its essential role in exercise-induced health benefits. Further investigations showed that CLCF1 enhances mitochondrial function in muscle cells, inhibits osteoclast development (which promotes bone breakdown), and stimulates osteoblast differentiation (which promotes bone formation).
This discovery offers a new perspective on the biological mechanisms behind age-related decline in musculoskeletal health. Dr. Yang emphasized that understanding CLCF1’s role could lead to innovative therapies to address sarcopenia and osteoporosis, common age-associated conditions.
In summary, this research provides a biological explanation for why exercise becomes less beneficial with age and opens pathways for developing targeted treatments to promote healthier aging. For more information, visit source.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
How Psychedelics and Non-Hallucinogenic Analogs Interact with the Brain Receptor
New research uncovers how both psychedelic and non-hallucinogenic compounds activate the same brain receptor to promote neuroplasticity and antidepressant effects, offering hope for safer mental health therapies.
Can Ozempic Help Lower Your Risk of Dementia?
Emerging research suggests that Ozempic's active ingredient, semaglutide, may help lower the risk of vascular dementia in people with type 2 diabetes through its anti-inflammatory and metabolic benefits.
Innovative AI Tool Enhances Cancer Tissue Analysis for Better Diagnostics
Mount Sinai researchers have introduced MARQO, an AI-powered platform that significantly improves the accuracy and efficiency of cancer tissue analysis, paving the way for advancements in diagnosis and personalized treatment.
The 'Badscopal Effect': High-Dose Radiation Therapy May Promote Growth in Untreated Distant Tumors
New research uncovers the 'badscopal effect,' where high-dose radiation therapy can unexpectedly promote growth in untreated metastatic tumors, highlighting the need for combined targeted treatments.